Glioblastoma, Cancer Stem Cells and Hypoxia

Glioblastoma (GBM) prognosis remains dismal, with most patients succumbing to disease within 1 or 2 years of diagnosis. Recent studies have suggested that many solid tumors, including GBM, are maintained by a subset of cells termed cancer stem cells (CSCs). It has been shown that these cells are inherently radio‐ and chemotherapy resistant, and may be maintained in vivo in a niche characterized by reduced oxygen tension (hypoxia). This review examines the recently described effects of hypoxia on CSC in GBM, and the potential promise in targeting the hypoxic pathway therapeutically.

[1]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Argyriou,et al.  Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas , 2009, Oncology.

[3]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[4]  U. Lendahl,et al.  Hypoxia requires notch signaling to maintain the undifferentiated cell state. , 2005, Developmental cell.

[5]  G. Fuller.  The WHO Classification of Tumours of the Central Nervous System, 4th edition. , 2009, Archives of pathology & laboratory medicine.

[6]  K. Camphausen,et al.  CD133+ Glioblastoma Stem-like Cells are Radiosensitive with a Defective DNA Damage Response Compared with Established Cell Lines , 2009, Clinical Cancer Research.

[7]  G. Semenza,et al.  Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. , 1993, The Journal of biological chemistry.

[8]  C. Zimmer,et al.  Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. , 2010, Neuro-oncology.

[9]  Peter T. Nelson,et al.  Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding , 2004, Cancer Research.

[10]  R Fankhauser,et al.  Tumours of the nervous system. , 1974, Bulletin of the World Health Organization.

[11]  M. Won,et al.  LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. , 2010, Biochemical pharmacology.

[12]  L. Wartman,et al.  Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. , 1998, Gene expression.

[13]  R. Jensen,et al.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target , 2009, Journal of Neuro-Oncology.

[14]  G. Semenza,et al.  Induction of Hypoxia-inducible Factor 1 Activity by Muscarinic Acetylcholine Receptor Signaling* , 2004, Journal of Biological Chemistry.

[15]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[16]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[17]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[18]  R. Roberts,et al.  Low O2 tensions and the prevention of differentiation of hES cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Zhang,et al.  NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. , 2008, Breast cancer research and treatment.

[20]  S. Påhlman,et al.  The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. , 2010, Current topics in microbiology and immunology.

[21]  E. Monti,et al.  The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. , 2010, Biochemical pharmacology.

[22]  M. Dewhirst,et al.  Microvascular studies on the origins of perfusion-limited hypoxia. , 1996, The British journal of cancer. Supplement.

[23]  H. Kiyonari,et al.  Glioblastoma Formation from Cell Population Depleted of Prominin1-Expressing Cells , 2009, PloS one.

[24]  D. Livingston,et al.  Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. , 2004, Cancer cell.

[25]  Zhaobin Zhang,et al.  Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. , 2005, Cancer research.

[26]  A. Miki,et al.  Effects of oxygen concentration on embryonic development in rats: a light and electron microscopic study using whole-embryo culture techniques , 2004, Anatomy and Embryology.

[27]  R. Wechsler-Reya,et al.  Getting at the Root and Stem of Brain Tumors , 2004, Neuron.

[28]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[29]  J. Engh,et al.  Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.

[30]  A. Olivi,et al.  Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma , 2007, Stem cells.

[31]  N. Sang,et al.  Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. , 2006, Molecular and cellular biology.

[32]  S. Weiss,et al.  Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens , 2009, Stem cells.

[33]  R. Cole,et al.  RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. , 2007, Molecular cell.

[34]  T. Ichisaka,et al.  Generation of germline-competent induced pluripotent stem cells , 2007, Nature.

[35]  A. Harris,et al.  Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. , 2010, Cancer research.

[36]  Hao Zhang,et al.  NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells , 2008, Breast Cancer Research and Treatment.

[37]  P. Wesseling,et al.  Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.

[38]  Peter T. Nelson,et al.  Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.

[39]  M. Chopp,et al.  Inhibition of ADAM17 reduces hypoxia‐induced brain tumor cell invasiveness , 2007, Cancer science.

[40]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[41]  M. Wolter,et al.  A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. , 2010, Brain : a journal of neurology.

[42]  G. Maira,et al.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.

[43]  R. Cole,et al.  RACK1 Competes with HSP90 for Binding to HIF-1α and is Required for O2-independent and HSP90 Inhibitor-induced Degradation of HIF-1α , 2007 .

[44]  Austin G Smith,et al.  CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent , 2009, PloS one.

[45]  T. Kondo,et al.  Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Giaccia,et al.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.

[47]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[48]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[49]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[50]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[51]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[52]  T. Dilling,et al.  Imaging and Analytical Methods as Applied to the Evaluation of Vasculature and Hypoxia in Human Brain Tumors , 2008, Radiation research.

[53]  Jun O. Liu,et al.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells , 2009, Proceedings of the National Academy of Sciences.

[54]  Rusha Thomas,et al.  A HIF‐1α‐dependent autocrine feedback loop promotes survival of serum‐deprived prostate cancer cells , 2009, The Prostate.

[55]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[56]  R. McLendon,et al.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype , 2009, Cell cycle.

[57]  U. Lendahl,et al.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.

[58]  B. Sullenger,et al.  Notch Promotes Radioresistance of Glioma Stem Cells , 2009, Stem cells.

[59]  Peter Devilee,et al.  Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. , 2007, International journal of cancer.

[60]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[61]  S. Moore,et al.  Vascular Smooth Muscle Hyperplasia Underlies the Formation of Glomeruloid Vascular Structures of Glioblastoma Multiforme , 1992, Journal of neuropathology and experimental neurology.

[62]  Yiting Cao,et al.  Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  E. Wong,et al.  Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[64]  V. Amberger-Murphy.  Hypoxia helps glioma to fight therapy. , 2009, Current cancer drug targets.

[65]  E. Stanbridge,et al.  Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1α C-Terminal Activation Domain , 2006, Molecular and Cellular Biology.

[66]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[67]  T. Nagashima,et al.  Proliferative potential of vascular components in human glioblastoma multiforme , 2004, Acta Neuropathologica.

[68]  L. Ellis,et al.  Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. , 2003, The American journal of pathology.

[69]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[70]  Jiri Zavadil,et al.  Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres , 2010, Molecular Cancer.

[71]  Xiaoling Zhang,et al.  Hypoxia-induced Nucleophosmin Protects Cell Death through Inhibition of p53* , 2004, Journal of Biological Chemistry.

[72]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[73]  Daniel J Brat,et al.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. , 2005, Neuro-oncology.

[74]  A. Giaccia,et al.  Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. , 2003, Molecular and cellular biology.

[75]  Hans Skovgaard Poulsen,et al.  The functional role of Notch signaling in human gliomas. , 2010, Neuro-oncology.

[76]  L. Neckers,et al.  Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway* , 2002, The Journal of Biological Chemistry.

[77]  M. Ohh,et al.  The role of hypoxia-inducible factors in cancer , 2007, Cellular and Molecular Life Sciences.

[78]  T. Zhao,et al.  Characteristics of Neural Stem Cells Expanded in Lowered Oxygen and the Potential Role of Hypoxia-Inducible Factor-1Alpha , 2007, Neurosignals.

[79]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[80]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[81]  David J. Anderson,et al.  Culture in Reduced Levels of Oxygen Promotes Clonogenic Sympathoadrenal Differentiation by Isolated Neural Crest Stem Cells , 2000, The Journal of Neuroscience.

[82]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[83]  Guido Nikkhah,et al.  NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.

[84]  G. Semenza,et al.  Regulation of oxygen homeostasis by hypoxia-inducible factor 1. , 2009, Physiology.

[85]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[86]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[87]  D. Steindler,et al.  Residual tumor cells are unique cellular targets in glioblastoma , 2010, Annals of neurology.

[88]  D. Panchision,et al.  The role of oxygen in regulating neural stem cells in development and disease , 2009, Journal of cellular physiology.

[89]  Yi-Wei Chen,et al.  Identification of CD133-Positive Radioresistant Cells in Atypical Teratoid/ Rhabdoid Tumor , 2008, PloS one.

[90]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[91]  R. Scienza,et al.  Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma , 2010, Stem cells.

[92]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[93]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[94]  A. Weljie,et al.  Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. , 2011, The international journal of biochemistry & cell biology.

[95]  J. Knisely,et al.  Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[96]  L. Neckers,et al.  Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. , 2002, The Journal of biological chemistry.

[97]  A. Harris,et al.  Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression , 2007, Journal of Molecular Medicine.

[98]  G. Maki,et al.  Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. , 2007, International journal of radiation oncology, biology, physics.

[99]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[100]  Peter Canoll,et al.  Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. , 2008, Neurosurgery.

[101]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[102]  Markus Bredel,et al.  Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes , 2003, Brain pathology.

[103]  N. Sang,et al.  Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. , 2006, The Journal of biological chemistry.

[104]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[105]  Nadine Kabbani,et al.  Enhanced Proliferation, Survival, and Dopaminergic Differentiation of CNS Precursors in Lowered Oxygen , 2000, The Journal of Neuroscience.

[106]  R. Bajpai,et al.  Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. , 2008, Cancer research.

[107]  A. Giaccia,et al.  Hypoxia-Induced Gene Expression Occurs Solely through the Action of Hypoxia-Inducible Factor 1α (HIF-1α): Role of Cytoplasmic Trapping of HIF-2α , 2003, Molecular and Cellular Biology.

[108]  A. Maity,et al.  EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. , 2006, Cancer research.

[109]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[110]  L. Aaltonen,et al.  Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability , 2007 .

[111]  D. Benos,et al.  CD133 Is a Marker of Bioenergetic Stress in Human Glioma , 2008, PloS one.

[112]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[113]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[114]  Loic Deleyrolle,et al.  Enumeration of Neural Stem and Progenitor Cells in the Neural Colony‐Forming Cell Assay , 2008, Stem cells.

[115]  J. Mendelsohn,et al.  The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression , 2005, Oncogene.

[116]  N. Sang,et al.  Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-inducible Factors Independently of Direct Acetylation of HIF-α* , 2006, Journal of Biological Chemistry.

[117]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[118]  D. Gillespie,et al.  Silencing of Hypoxia Inducible Factor-1α by RNA Interference Attenuates Human Glioma Cell Growth In vivo , 2007, Clinical Cancer Research.

[119]  G. Morriss,et al.  Effect of oxygen concentration on morphogenesis of cranial neural folds and neural crest in cultured rat embryos. , 1979, Journal of embryology and experimental morphology.

[120]  C. Eberhart,et al.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.

[121]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[122]  ChB PhD MRCPath T. H. Moss MB.  Tumours of the Nervous System , 1986, Springer London.

[123]  D. Stearns,et al.  Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. , 2006, Cancer research.

[124]  G. Melillo.  Targeting hypoxia cell signaling for cancer therapy , 2007, Cancer and Metastasis Reviews.

[125]  E. Fuchs,et al.  Socializing with the Neighbors Stem Cells and Their Niche , 2004, Cell.

[126]  L. Denaro,et al.  Hypoxia and HIF1α Repress the Differentiative Effects of BMPs in High‐Grade Glioma , 2009, Stem cells.

[127]  N. Sang,et al.  Histone Deacetylase Inhibitors Induce VHL and Ubiquitin-Independent Proteasomal Degradation of Hypoxia-Inducible Factor 1α , 2006, Molecular and Cellular Biology.

[128]  Savita Khanna,et al.  Oxygen Sensing by Primary Cardiac Fibroblasts: A Key Role of p21Waf1/Cip1/Sdi1 , 2003, Circulation research.

[129]  J. Tait,et al.  Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.

[130]  J. Uhm.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2010 .

[131]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[132]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.

[133]  D. Israeli,et al.  Activation of p53 and its target genes p21(WAF1/Cip1) and PAG608/Wig-1 in ischemic preconditioning. , 1999, Brain research. Molecular brain research.

[134]  I. Radovanovic,et al.  Limits of CD133 as a marker of glioma self‐renewing cells , 2009, International journal of cancer.

[135]  A. Maitra,et al.  Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration , 2008, Molecular Cancer Therapeutics.

[136]  P. Vajkoczy,et al.  Angiogenesis in malignant glioma--a target for antitumor therapy? , 2006, Critical reviews in oncology/hematology.

[137]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[138]  Yuichi Makino,et al.  Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.

[139]  K. Camphausen,et al.  Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro , 2009, Molecular Cancer Research.

[140]  P. Giannakakou,et al.  Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. , 2005, Cancer research.

[141]  Dong-Sup Lee,et al.  Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas , 2008, Laboratory Investigation.

[142]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[143]  Jianjun Tang,et al.  Hypoxia‐inducible factor‐1α blocks differentiation of malignant gliomas , 2009, The FEBS journal.

[144]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.